BACKGROUND: Dysfunctional immune responses characterize sarcoidosis, but the status of cathelicidin, a potent immunoregulatory and antimicrobial molecule, has not been established in clinical disease activity. METHODS: Alveolar macrophage cathelicidin expression was determined in biopsy-proven sarcoidosis patients classified clinically as 'severe' (requiring systemic treatment) or 'non-severe' (never requiring treatment). Bronchoalveolar lavage (BAL) cells from sarcoidosis patients and healthy controls were analyzed for mRNA expression of cathelicidin, vitamin D receptor (VDR) and the VDR coactivator steroid receptor coactivator-3 (SRC3) by quantitative PCR. Cathelicidin-derived peptide LL-37 was determined by immunocytochemistry. Serum calcidiol (25-hydroxyvitamin D2; vitD2) and calcitriol (1,25-dihydroxyvitamin D3; vitD3) were quantified. RESULTS: The results indicated reduced BAL cell expression of cathelicidin and SRC3 in severe but not non-severe sarcoidosis compared to controls. Serum levels of biologically active vitD3 in both severe and non-severe patients were within the control range even though vitD2 levels in both groups were below the recommended level (30 ng/ml). Sarcoidosis and control alveolar macrophages were studied in vitro to determine cathelicidin responses to vitD3 and tumor necrosis factor-α (TNFα), a vitD3 antagonist elevated in active sarcoidosis. Alveolar macrophage cathelicidin was stimulated by vitD3 but repressed by TNFα, which also repressed SRC3. CONCLUSIONS: These findings suggest that TNFα-mediated repression of SRC3 contributes to alveolar macrophage cathelicidin deficiency in severe sarcoidosis despite healthy vitD3 levels. Deficiency of cathelicidin, a multifunctional regulator of immune cells and proinflammatory cytokines, may impede resolution of inflammation in the lungs of patients with severe sarcoidosis.
BACKGROUND: Dysfunctional immune responses characterize sarcoidosis, but the status of cathelicidin, a potent immunoregulatory and antimicrobial molecule, has not been established in clinical disease activity. METHODS: Alveolar macrophage cathelicidin expression was determined in biopsy-proven sarcoidosispatients classified clinically as 'severe' (requiring systemic treatment) or 'non-severe' (never requiring treatment). Bronchoalveolar lavage (BAL) cells from sarcoidosispatients and healthy controls were analyzed for mRNA expression of cathelicidin, vitamin D receptor (VDR) and the VDR coactivator steroid receptor coactivator-3 (SRC3) by quantitative PCR. Cathelicidin-derived peptide LL-37 was determined by immunocytochemistry. Serum calcidiol (25-hydroxyvitamin D2; vitD2) and calcitriol (1,25-dihydroxyvitamin D3; vitD3) were quantified. RESULTS: The results indicated reduced BAL cell expression of cathelicidin and SRC3 in severe but not non-severe sarcoidosis compared to controls. Serum levels of biologically active vitD3 in both severe and non-severe patients were within the control range even though vitD2 levels in both groups were below the recommended level (30 ng/ml). Sarcoidosis and control alveolar macrophages were studied in vitro to determine cathelicidin responses to vitD3 and tumornecrosis factor-α (TNFα), a vitD3 antagonist elevated in active sarcoidosis. Alveolar macrophage cathelicidin was stimulated by vitD3 but repressed by TNFα, which also repressed SRC3. CONCLUSIONS: These findings suggest that TNFα-mediated repression of SRC3 contributes to alveolar macrophage cathelicidin deficiency in severe sarcoidosis despite healthy vitD3 levels. Deficiency of cathelicidin, a multifunctional regulator of immune cells and proinflammatory cytokines, may impede resolution of inflammation in the lungs of patients with severe sarcoidosis.
Authors: O E Sørensen; P Follin; A H Johnsen; J Calafat; G S Tjabringa; P S Hiemstra; N Borregaard Journal: Blood Date: 2001-06-15 Impact factor: 22.113
Authors: Daniel A Culver; Barbara P Barna; Baisakhi Raychaudhuri; Tracey L Bonfield; Susamma Abraham; Anagha Malur; Carol F Farver; Mani S Kavuru; Mary Jane Thomassen Journal: Am J Respir Cell Mol Biol Date: 2003-09-25 Impact factor: 6.914
Authors: Tian-Tian Wang; Frederick P Nestel; Véronique Bourdeau; Yoshihiko Nagai; Qiuyu Wang; Jie Liao; Luz Tavera-Mendoza; Roberto Lin; John W Hanrahan; Sylvie Mader; John H White; John H Hanrahan Journal: J Immunol Date: 2004-09-01 Impact factor: 5.422
Authors: Tracey L Bonfield; Baisakhi Raychaudhuri; Anagha Malur; Susamma Abraham; Bruce C Trapnell; Mani S Kavuru; Mary Jane Thomassen Journal: Am J Physiol Lung Cell Mol Physiol Date: 2003-08-01 Impact factor: 5.464
Authors: Tracey L Bonfield; Carol F Farver; Barbara P Barna; Anagha Malur; Susamma Abraham; Baisakhi Raychaudhuri; Mani S Kavuru; Mary Jane Thomassen Journal: Am J Respir Cell Mol Biol Date: 2003-06-12 Impact factor: 6.914
Authors: Maria Bucova; Magda Suchankova; Elena Tibenska; Eva Tedlova; Juraj Demian; Ivan Majer; Helena Novosadova; Miroslav Tedla Journal: Mediators Inflamm Date: 2015-06-16 Impact factor: 4.711
Authors: Łukasz Gwadera; Adam Jerzy Białas; Mikołaj Aleksander Iwański; Paweł Górski; Wojciech Jerzy Piotrowski Journal: Chron Respir Dis Date: 2019 Jan-Dec Impact factor: 2.444